BACKGROUND: Carbapenemase-producing Pseudomonas aeruginosa is a serious threat in hospital infection due to its multidrug resistance.
Introduction
C arbapenem-resistant Pseudomonas aeruginosa (CRPA) is listed as an organism posing a serious threat by the Centers for Disease Control and Prevention. [1] In India, up to 40% P. aeruginosa isolates are shown to be carbapenem resistant. [2] Carbapenem resistance in P. aeruginosa has shown to be multifactorial, including production of carbapenemase, overexpression/ overproduction of efflux pump, and porin loss. Carbapenemases in P. aeruginosa belong to three molecular classes, for example, class A ( bla KPC), class B ( bla IMP, bla VIM, bla NDM, bla SIM, bla GIM, and bla SPM), and class D ( bla OXA-48) genes. The molecular mechanism of carbapenem resistance in P. aeruginosa has been studied in very few studies restricted to North and South India. [2, 3] The aim of the present study was to determine the production of carbapenemase enzymes in CRPA isolates by phenotypic methods (double-disk synergy test [DDST] and combined disk synergy test [CDST] ) and to determine the prevalence of bla KPC, bla NDM-1, bla IMP, bla VIM, bla SIM, bla SPM, bla GIM, and bla OXA-48. The susceptibility profile of P. aeruginosa to other antipseudomonal antibiotics was also investigated.
Materials and Methods
This study was conducted at the microbiology department of a tertiary care teaching hospital from January 2017 to May 2018. All consecutive nonduplicate isolates of P. aeruginosa from different clinical samples (blood, respiratory sample, pus, urine, sterile body fluids, and other samples) resistant to meropenem and/or imipenem by disk diffusion method were included in the study. The study was conducted after ethical clearance from the Institutional Ethics Committee (ref no-IEC/ AIIMS BBSR/PG Thesis/2017-18/3).
The initial isolation and identification of P. aeruginosa were carried out by standard bacteriological procedures. The following antimicrobials were tested by disk diffusion: ceftazidime (30 µg), cefepime (30 µg), piperacillintazobactam (100 µg/10 µg), ticarcillin-clavulanate (75 µg/10 µg), imipenem (10 µg), meropenem (10 µg), doripenem (10 µg), amikacin (30 µg), gentamicin (10 µg), netilmicin (30 µg), tobramycin (10 µg), ciprofloxacin (5 µg), and levofloxacin (5 µg) (HiMedia Laboratories Pvt. Ltd., Mumbai, Maharashtra, India). The antimicrobial susceptibility was interpreted as per the Clinical and Laboratory Standards Institute 2017 guidelines using P. aeruginosa ATCC strain 27853 as quality control strain. [4] In addition, imipenem and meropenem minimum inhibitory concentration was determined by agar dilution and E-test (HiMedia Laboratories Pvt. Ltd., Mumbai, Maharashtra, India).
Isolates with imipenem/meropenem/doripenem MIC ≥8 µg/ml by agar dilution and E-test were screened for carbapenemase production by DDST and CDST by the following methods. • Double-disk synergy test: [5] As described by Lee et al., this test was carried out using ethylenediaminetetraacetic acid (EDTA) disk (10 µl of 0.5 M EDTA) and the imipenem disk (10 µg) using the standard method. [5] The production of large synergistic inhibitory zones was interpreted as test positive for metallo-beta-lactamase (MBL) • Combined disk synergy test: [6] As described by Yong et al., this test was carried out using two imipenem commercial disks with and without EDTA (10 µl of 0.5 M EDTA). [6] The zone of inhibition diameter with imipenem + EDTA disk ≥7 mm than the imipenem disk alone was considered positive for MBL production.
Molecular detection of carbapenemase gene
Multiplex polymerase chain reaction (PCR) for the presence of bla KPC, bla NDM-1, bla IMP, bla VIM, bla SIM, bla SPM, bla GIM, and bla OXA-48 was carried out according to the method published by Ellington et al. [7] and Kumarasamy et al. [8] Briefly, DNA extraction from P. aeruginosa isolates was carried out using QIAamp DNA Mini kit spin-column method (QIAGEN, Hilden, Germany) as per manufacturer's instruction. Two sets of multiplex PCR were done using KAPA2G Fast Multiplex PCR Kit (2X) as per manufacturer's instructions (Kapa Biosystems, Cape Town, South Africa). The first set of multiplex PCR detected bla IMP, VIM, GIM, SPM, and SIM and the second set of multiplex PCR detected bla NDM-1, OXA-48, and KPC. The PCR reactions consisted of a final reaction volume of 25 µl containing 5 µl of template DNA, 12.5 µl of 2X KAPA2G Fast Multiplex Master Mix, and 0.5 µl of each oligonucleotide primer. Amplification was done with initial denaturation step at 95°C for 3 min, followed by denaturation at 95°C for 15 s, annealing at 60°C for 30 s, extension at 72°C for 30 s, and a final extension step at 72°C for 7 min. The product was visualized by 1.5% agarose gel electrophoresis, stained with ethidium bromide, and was viewed under automated gel documentation system (Syngene G: Box, Syngene, Cambridge, U.K.) using ultraviolet illumination. The primer sequences and the product sizes [7, 8] are given in Table 1 .
Statistical analysis
The sensitivity and specificity of CDST and DDST were calculated by forming 2 × 2 contingency tables and genotypic tests being considered as a gold standard. VIM and bla NDM-1 genes. Four isolates were found to harbor a combination of three carbapenem-resistant genes [ Figure 3 ]. No CRPA isolates were found to possess bla IMP, bla KPC, and bla OXA-48. The distribution of various carbapenemase genes in 102 CRPA isolates is provided in Table 2 . Five isolates of CRPA that were positive for NDM-1 were sent for sequencing by Sanger's method to Eurofins Genomics India Pvt. Ltd., Bengaluru, Karnataka, India, and interpreted using BLAST software (NIH, USA), of which three were NDM-1 and two were found to be NDM-5. The sensitivity of DDST and CDST was found calculated taking the presence of any MBL gene as a reference test and was found to be 81.35% and 92.18%, respectively, as shown in Table 3 .
Discussion
Carbapenem resistance was noted in 18.2% P. aeruginosa isolates in our study. In the Indian Council of Medical Research scoping document, the prevalence of CRPA isolates across Indian hospitals is shown to be 42%-47% in the years 2014 and 2015. [9] In a recent single-center study from North India, the prevalence of CRPA is shown to be 72.5% in admitted patients. [10] The relatively lower prevalence of CRPA in our study could be due to In our study, the sensitivity of DDST and CDST was found to be 81.35% and 92.18%, respectively (taking the presence of any MBL gene as a reference test). The sensitivity of CDST for MBL detection was shown to be 86.7% and specificity of 51.1% in a previous study by Peter et al. in 2014. [11] The higher sensitivity of CDST compared to DDST, as observed in our study, is also described previously. [12] In the present study, the prevalence of MBL was 15.74% by phenotypic method (CDST), whereas the prevalence by genotypic method for MBL was found as 10.19%. The concordance rate between CDST and genotypic method of MBL detection in our study was found to be 92.18%. The overall rate of concordance between phenotypic and genotypic tests for the detection of MBL was 98% in a study by Kazi et al. [13] In our study, 62.74% CRPA isolates had at least one carbapenemase gene. bla VIM was the most prevalent gene in CRPA (30/64, 46.87%), followed by bla NDM-1 (29/64, 45.31%). bla VIM and bla NDM are shown to the most prevalent carbapenemase gene in the majority of Indian studies. [2, 3, 12, 14] In the study by Ellapan et al. in 2018, bla VIM and bla NDM were present in 23.1% and 17.3% of 156 CRPA isolates. [15] In another study by Mohanam and Menon in 2017, bla VIM and bla NDM were present in 32% and 27% of 213 CRPA isolates. [16] In a multicentric study from India, bla VIM and bla NDM were the most frequent carbapenemases in CRPA isolates with regional differences in the carbapenemase profile across the study sites. [2] The incidence of CRPA has increased worldwide, and they pose a potential risk for therapeutic failure with the empirical treatments currently in place. In this study, no bla KPC, bla IMP, and bla OXA-48 were identified. bla KPC and bla OXA-48 were also absent in 156 CRPA isolates analyzed by Ellapan et al. [15] In another multicentric study by Khurana et al., bla KPC and bla OXA-1 were present in 43% and 56% of CRPA isolates from North India but were absent in CRPA isolates collected from South India. [17] In the present study, 15 CRPA isolates had coexistence of two or three carbapenem-resistant genes. bla VIM + bla NDM-1 was the most common combination (6/102, 5.88%), followed by bla VIM + bla GIM (3/102, 2.94%). The coproduction of bla VIM + bla NDM-1 had previously been described in 7.1% CRPA isolates by Ellapan et al. [15] The coexistence of bla VIM + bla NDM-1 and bla KPC-2 and bla NDM-1 in CRPA isolates from India is also described previously by Paul et al. [18, 19] No carbapenem-resistant gene was detected in 38 (38/102, 37.25%) CRPA isolates in our study. Other carbapenem mechanisms such as efflux pump and porin loss could have contributed for carbapenemase resistance, which were not studied in the present study. Loss of OprD porin and overexpression of mexA gene is also found in studies from India either as a standalone mechanism or in association with the presence of bla VIM. [15] In our study, fluoroquinolones did not have any activity against CRPA isolates. Polymyxin B and colistin were found to be susceptible in all isolates of P. aeruginosa.
There are recent studies of colistin resistance in <5% P. aeruginosa isolates from India, which warrant judicious use of this last-resort antibiotic. [14] Among beta-lactam and beta-lactamase inhibitor combination, the maximum susceptibility was observed for piperacillin-tazobactam (16.67%), followed by ceftazidime with 11.76% and 2.94% for ticarcillin-clavulanate which was found to be least susceptible. Carbapenem-resistant and cephalosporin-susceptible P. aeruginosa is a rare phenotype. Previous carbapenem therapy and decreased OprD expression and efflux system overexpression are cited as possible mechanisms of this phenotype. The clinical utility in this group is, however, debatable. [20] Conclusion A high rate of carbapenemase production was observed in P. aeruginosa. Coproducers of multiple carbapenemases are also a cause of concern. An in-depth understanding of molecular mechanisms of resistance will be helpful in optimizing patient management and hospital infection control.
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